{"id":11547,"date":"2026-03-18T18:13:40","date_gmt":"2026-03-18T09:13:40","guid":{"rendered":"https:\/\/rightfoundation.kr\/en\/?p=11547"},"modified":"2026-03-19T09:29:30","modified_gmt":"2026-03-19T00:29:30","slug":"sk-bioscience-secures-funding-to-advance-rsv-preventive-antibody-development-with-right-foundation-support","status":"publish","type":"post","link":"https:\/\/rightfoundation.kr\/en\/sk-bioscience-secures-funding-to-advance-rsv-preventive-antibody-development-with-right-foundation-support\/","title":{"rendered":"SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"11547\" class=\"elementor elementor-11547\">\n\t\t\t\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-22110e80 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"22110e80\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7581e584\" data-id=\"7581e584\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-79c9ffeb elementor-widget elementor-widget-stad_for_elementor_heading\" data-id=\"79c9ffeb\" data-element_type=\"widget\" data-widget_type=\"stad_for_elementor_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\r\n\t<div class=\"stad-heading stad-heading-single-content stad-padding-0 stad-margin-0\">\t\t<span class=\"stad-heading-single-content-text stad-heading-content-text stad-inline-block\">\r\n\t\t\t\t\t\t\t<span class=\"stad-heading-single-content-text-content\">SK bioscience Secures Funding to Advance RSV Preventive Antibody Development<\/span>\r\n\t\t\t\t\t<\/span>\r\n\t<\/div>\t\r\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5c9be6c elementor-widget elementor-widget-stad_for_elementor_heading\" data-id=\"5c9be6c\" data-element_type=\"widget\" data-widget_type=\"stad_for_elementor_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\r\n\t<div class=\"stad-heading stad-heading-single-content stad-padding-0 stad-margin-0\">\t\t<span class=\"stad-heading-single-content-text stad-heading-content-text stad-inline-block\">\r\n\t\t\t\t\t\t\t<span class=\"stad-heading-single-content-text-content\">The RIGHT Foundation will award a KRW 4 billion grant to SK bioscience for the \u201cDevelopment of an Affordable Monoclonal Antibody for RSV Prevention\u201d project.<\/span>\r\n\t\t\t\t\t<\/span>\r\n\t<\/div>\t\r\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4161c14 elementor-widget elementor-widget-text-editor\" data-id=\"4161c14\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.12.1 - 02-04-2023 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p>Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibody<br \/>Technology licensed from Gates MRI; early studies confirm suppression of RSV infection<br \/>Targeting global markets while addressing unmet needs in developing countries<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c3f7b44 elementor-widget elementor-widget-text-editor\" data-id=\"c3f7b44\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div>SK bioscience announced on 18 that it has entered into a funding agreement with the Research Investment for Global Health Technology Foundation (RIGHT Foundation) to receive financial support for early clinical development of its RSV (respiratory syncytial virus) preventive monoclonal antibody candidate, RSM01.<\/div><div>\u00a0<\/div><div>The agreement was made through the RIGHT Foundation\u2019s Product Development Award (PDA). The RIGHT Foundation, established through a public-private partnership to advanced global health equity, awarded. SK bioscience secured KRW 4 billion (approximately USD 3.0 million) ? the largest grant available per project. Based on this support, the company plans to accelerate a Phase 1b clinical trial of RSM01 in infants.<\/div><div>\u00a0<\/div><div>RSM01 is a candidate RSV preventive therapeutic that SK bioscience licensed earlier this month from the Gates Medical Research Institute (Gates MRI), a nonprofit medical research organization. The candidate was designed by U.S. biotechnology company Adimab in collaboration with Gates MRI, which completed early research and a Phase 1a clinical trial. SK bioscience will oversee subsequent stages from the Phase 1b clinical trial through process development and commercialization.<\/div><div>\u00a0<\/div><div>RSM01 is designed to provide continuous protection throughout the RSV season with a single administration in newborns and infants. Non-clinical studies demonstrated effective suppression of RSV infection and replication, including activity against certain RSV strains with reduced responsiveness to existing preventive products.<\/div><div>\u00a0<\/div><div>Through the licensing agreement, SK bioscience obtained exclusive global supply rights, including high-income markets (non-exclusive in India and Gavi-eligible countries. Accordingly, the company plans a dual commercialization strategy: maximizing commercial value in advanced markets while supplying affordable doses through large-scale manufacturing to address unmet medical needs in lower-income countries.<\/div><div>\u00a0<\/div><div>RSV is a major respiratory virus causing severe lower respiratory tract infections in infants and young children worldwide, resulting in substantial hospitalizations and healthcare burden annually. According to global market research firm Evaluate Pharma, the global RSV preventive antibody market is projected to reach USD 4.5 billion (approximately KRW 6.6 trillion) by 2032. With limited currently available products and expanding immunization coverage in high-income countries, the market is expected to grow further.<\/div><div>\u00a0<\/div><div>Jinseon Park, COO of SK bioscience, said, \u201cThis funding agreement recognizes both the potential of the technology licensed from Gates MRI and our commitment to protecting global public health. By leveraging SK bioscience\u2019s world-class R&amp;D and manufacturing capabilities, we will develop a globally competitive product.\u201d<\/div><div>\u00a0<\/div><div>In addition to the RSV preventive antibody, SK bioscience continues to strengthen its mid- to long-term growth foundation through a diversified infectious disease pipeline, including next-generation pneumococcal vaccines, universal coronavirus vaccines, avian influenza vaccines, and mRNA and next-generation vaccine platforms. The company aims to secure global competitiveness through an integrated development strategy connecting R&amp;D, process development, manufacturing, and supply.<\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-7b42229c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7b42229c\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-1a79e19b\" data-id=\"1a79e19b\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f1d567a elementor-align-left elementor-mobile-align-left elementor-widget elementor-widget-button\" data-id=\"f1d567a\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t<a href=\"https:\/\/www.skbioscience.com\/en\/news\/news_01_01?mode=2&#038;id=342&#038;page=1\" target=\"_blank\" rel=\"nofollow\" class=\"elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-text\">Article<\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-217a68c1\" data-id=\"217a68c1\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5749a4b7 elementor-align-right elementor-mobile-align-left elementor-widget elementor-widget-button\" data-id=\"5749a4b7\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t<a href=\"\/en\/partner-news\/\" class=\"elementor-button-link elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-text\">Partner News List<\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-54a5a5cf elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"54a5a5cf\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-341b078a\" data-id=\"341b078a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>SK bioscience Secures Funding to Advance RSV Preventive Antibody Development The RIGHT Foundation will award a KRW 4 billion grant to SK bioscience for the \u201cDevelopment of an Affordable Monoclonal Antibody for RSV Prevention\u201d project. Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibodyTechnology licensed from Gates MRI; early&#8230;<\/p>\n","protected":false},"author":1,"featured_media":11548,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[9],"tags":[],"jetpack_featured_media_url":"https:\/\/rightfoundation.kr\/en\/wp-content\/uploads\/sites\/2\/2026\/03\/sk.png","_links":{"self":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts\/11547"}],"collection":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/comments?post=11547"}],"version-history":[{"count":7,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts\/11547\/revisions"}],"predecessor-version":[{"id":11555,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/posts\/11547\/revisions\/11555"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/media\/11548"}],"wp:attachment":[{"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/media?parent=11547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/categories?post=11547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rightfoundation.kr\/en\/wp-json\/wp\/v2\/tags?post=11547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}